• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Theravance/Glaxo’s Breo Ellipta wins FDA go-ahead

Theravance/Glaxo’s Breo Ellipta wins FDA go-ahead

May 15, 2013 By Ingrid Mezo

Theravance/Glaxo's Breo Ellipta wins FDA go-ahead

GlaxoSmithKline (NYSE:GSK) and Theravance (NSDQ:THRX) won FDA approval for their co-developed Breo Ellipta inhaler for treatment of airflow obstructions, including bronchitis and emphysema in patients with chronic obstructive pulmonary disease.

The once daily, long-term maintenance inhaler is also indicated to reduce COPD exacerbations in patients with a history of such flare-ups, the companies said.

Breo Ellipta is a combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2 agonist vilanterol and is delivered to the patient using Theravance’s Ellipta, a new dry powder inhaler.

"The FDA approval of Breo Elipta brings an important inhaled, once-daily maintenance therapeutic option to COPD patients and doctors across the United States," Theravance CEO Rick Winningham said in a press statement. "After more than a decade of joint respiratory research and development, the approval is a very important milestone for Theravance and GSK."

Theravance and GlaxoSmithKline anticipate rolling out Breo Ellipta in the U.S. during the third quarter of fiscal 2013. Under previously set terms, FDA approval of Breo Ellipta obligates Theravance to make a milestone payment of $30 million to GSK.

The National Heart, Lung and Blood Institute estimates that as many as 27 million people in the US alone are affected by COPD, a number that is predicted to increase, the companies pointed out.

"This approval means that we can now realize our plan to bring Breo Ellipta to appropriate COPD patients in the U.S.," head of GSK Global Respiratory Franchise Darrell Baker said in a press statement. "We know that one of the main issues for patients who have experienced a COPD exacerbation is concern about possible future episodes. Breo Ellipta will help patients breathe better day-to-day and reduce the risk of future exacerbations, with a once-daily inhalation."

GlaxoSmithKline and Theravance are also seeking regulatory approval of the inhaler, under the trade name Relvar Ellipta, in Europe and Japan, the companies said.

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), News Well Tagged With: GlaxoSmithKline plc, Pulmonary, Theravance

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy